About 22 results found for searched term "CXCR4-IN-1" (0.147 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M41799 | CXCR4-IN-1 | CXCR |
| CXCR4-IN-1 is a CXCR4 inhibitor (IC50: 20 nM). | ||
| M2041 | WZ 811 | CXCR |
| WZ811 is a highly competitive CXCR4 antagonist with oral activity. WZ811 effectively inhibited CXCR4/SDF-1 (also known as CXCL12) -mediated regulation of cAMP level (EC50=1.2 nM) and SDF-1-induced matrix glue invasion (EC50=5.2 nM) in cells. | ||
| M2381 | AMD3465 hexahydrobromide (AMD3465 ) | CXCR |
| GENZ-644494 hexahydrobromide | ||
| AMD3465 hexahydrobromide（AMD3465 ) is an effective CXCR4 antagonist that inhibits 12G5 mAb in SupT1 cells. The IC50 values of CXCL12AF647 and CXCR4 were 0.75 nM and 18 nM, respectively. AMD 3465 also effectively inhibited X4 HIV replication (IC50, 1-10 nM), but not R5 HIV replication. | ||
| M5165 | MSX-122 | CXCR |
| MSX-122 is a novel small molecule and partial CXCR4 antagonist, with potent inhibition of CXCR4/CXCL12 actions (IC50 = 10 nM). | ||
| M6217 | Mavorixafor | CXCR |
| AMD-070; AMD-11070 | ||
| Mavorixafor (AMD-070) is a potent and selective antagonist of CXCR4 with an IC50 value of 13 nM in a CXCR4 125I-SDF inhibition binding assay, and inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs. | ||
| M13938 | ALX 40-4C Trifluoroacetate | CXCR |
| ALX 40-4C Trifluoroacetate is a small peptide inhibitor of the chemokine receptor CXCR4, inhibits SDF-1 from binding CXCR4 with a Ki of 1 μM, and suppresses the replication of X4 strains of HIV-1; ALX 40-4C Trifluoroacetate also acts as an antagonist of the APJ receptor, with an IC50 of 2.9 μM. | ||
| M13939 | Mavorixafor trihydrochloride | CXCR |
| AMD-070 trihydrochloride | ||
| Mavorixafor trihydrochloride (AMD-070 trihydrochloride) is a potent, selective and orally available CXCR4 antagonist, with an IC50 value of 13 nM against CXCR4 125I-SDF binding, and also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC50 of 1 and 9 nM, respectively. | ||
| M13942 | IT1t dihydrochloride | CXCR |
| IT1t dihydrochloride is a potent CXCR4 antagonist; inhibits CXCL12/CXCR4 interaction with an IC50 of 2.1 nM. | ||
| M21429 | Recombinant Human SDF-1β/CXCL12 (E. coli) | Cytokines and Growth Factors |
| SDF1β; SDF-1 beta; CXCL-12 | ||
| Stromal cell-derived factor-1β (SDF-1β), also known as SCYB12, PBSF, and CXCL12, is an 8.3 kDa, heparin-bound member of the CXC(or α) chemokine family that signals via the CXCR4 receptor. Protein Construction: SDF-1β/CXCL12 (Lys22-Met93). Accession # P48061. | ||
| M24637 | Ulocuplumab | CXCR |
| BMS 936564; MDX 1338; Anti-Human CXCR4 Recombinant Antibody | ||
| Ulocuplumab (Anti-Human CXCR4 Recombinant Antibody/BMS-936564/MDX1338) is a fully human IgG4 anti-CXCR4 antibody. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models. | ||
| M25426 | Recombinant Mouse SDF-1 Protein (E. coli) | Cytokines and Growth Factors |
| Stromal cell-derived factor 1; CXCL12 | ||
| The stromal cell-derived factor-1 (SDF1), also known as CXCL12, is a small (8 kDa) cytokine highly conserved chemotactic cytokine belonging to the large family of CXC chemokines. SDF-1 binds primarily to CXC receptor 4 (CXCR4; CD184). The binding of CXCL12 to CXCR4 induces intracellular signaling through several divergent pathways initiating signals related to chemotaxis, cell survival and/or proliferation, increase in intracellular calcium, and gene transcription. | ||
| M25427 | Recombinant Human SDF-1 Protein (E. coli) | Cytokines and Growth Factors |
| Stromal cell-derived factor-1 | ||
| The human stromal cell-derived factor-1 (SDF1), also known as CXCL12, is a small (8 kDa) cytokine highly conserved chemotactic cytokine belonging to the large family of CXC chemokines. SDF-1 binds primarily to CXC receptor 4 (CXCR4; CD184). The binding of CXCL12 to CXCR4 induces intracellular signaling through several divergent pathways initiating signals related to chemotaxis, cell survival and/or proliferation, increase in intracellular calcium, and gene transcription. | ||
| M27720 | Balixafortide | CXCR |
| POL6326 | ||
| Balixafortide (POL6326) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC50 < 10 nM. Balixafortide shows 1000-fold selective for CXCR4 than a large panel of receptors including CXCR7. Balixafortide blocks β-arrestin recruitment and calcium flux with IC50s < 10 nM. Balixafortide is also a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent. Anti-cancer effects. | ||
| M27731 | NUCC-390 | CXCR |
| NUCC-390 is a novel and selective small-molecule CXCR4 receptor agonist. NUCC-390 induces internalization of CXCR4 receptors and acts in an opposite way of AMD3100. NUCC-390 promotes nerve recovery of function after neurodegeneration in vivo. | ||
| M28275 | USL311 | CXCR |
| USL311 is a potent and selective CXCR4 antagonist, with anti-tumor activity. USL311 prevents the binding of stromal-cell derived factor-1 (SDF-1 or CXCL12) to CXCR4. | ||
| M29306 | ICT5040 | CXCR |
| ICT5040 is a small molecule CXCR4 antagonist (IC50=3.8 μM). ICT5040 inhibits CXCL12-mediated proliferation and migration, and suppresses CXCL12-induced intracellular calcium mobilisation in U87 glioma cells. | ||
| M29790 | NUCC-390 dihydrochloride | CXCR |
| NUCC-390 dihydrochloride is a novel and selective small-molecule CXCR4 receptor agonist. NUCC-390 dihydrochloride induces internalization of CXCR4 receptors and acts in an opposite way of AMD3100. NUCC-390 dihydrochloride promotes nerve recovery of function after neurodegeneration in vivo. | ||
| M31026 | Balixafortide TFA | CXCR |
| POL6326 TFA | ||
| Balixafortide TFA (POL6326 TFA) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC50 < 10 nM. Balixafortide TFA shows 1000-fold selective for CXCR4 than a large panel of receptors including CXCR7. Balixafortide TFA blocks β-arrestin recruitment and calcium flux with IC50s < 10 nM. Balixafortide TFA is also a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent. Anti-cancer effects. | ||
| M41797 | Polyphemusin II-Derived Peptide | CXCR |
| Polyphemusin II-Derived Peptide (T140), a CXCR4 inhibitor, shows high inhibitory activity against HIV-1 entry. | ||
| M43958 | Recombinant Rat SDF-1/CXCL12 (E. coli) | Cytokines and Growth Factors |
| Stromal-Cell Derived Factor-1 alpha; CXCL12 alpha | ||
| SDF-1 also known as CXCL12 is belonging to the CXC chemokine family. SDF-1 binds primarily to CXC receptor 4 (CXCR4; CD184). The binding of CXCL12 to CXCR4 induces intracellular signaling through several divergent pathways initiating signals related to chemotaxis, cell survival and/or proliferation, increase in intracellular calcium, and gene transcription. | ||
| M53203 | ALX 40-4C | CXCR |
| ALX 40-4C is a small peptide inhibitor of the chemokine receptor CXCR4, inhibits SDF-1 from binding CXCR4 with a Ki of 1 μM, and suppresses the replication of X4 strains of HIV-1. | ||
| M54418 | FC131 TFA | CXCR |
| FC131 TFA is a CXCR4 antagonist, inhibits [125I]-SDF-1 binding to CXCR4, with an IC50 of 4.5 nM. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
